No | Trial type | Baseline HAQ | Previous No of DMARDs | Disease duration (years) | % Patients responding | |||||
---|---|---|---|---|---|---|---|---|---|---|
Moderate DAS28 | Good DAS28 | ACR20 | ACR50 | ACR70 | ||||||
eow, every other week; 2×weekly, twice weekly. | ||||||||||
Adalimumab | ||||||||||
40 mg eow + MTX6 | 67 | RCT | 1.6 | 2.9 | 12.2 | 72 | 54 | 67 | 55 | 27 |
40 mg eow + MTX7 | 207 | RCT | 1.5 | 2.4 | 11.0 | 72 | 35 | 62 | 39 | 21 |
40 mg eow8 | 113 | RCT | 1.8 | 3.8 | 10.6 | 47 | 9 | 46 | 22 | 12 |
Etanercept | ||||||||||
25 mg 2×wkly + MTX11 | 59 | RCT | 1.5 | 2.7 | 13 | NA | NA | 71 | 39 | 15 |
25 mg 2×wkly12 | 78 | RCT | 1.6 | 3.3 | 11 | NA | NA | 59 | 40 | 15 |
25 mg 2×wkly (46% monotherapy)14,15 | 123 | Observational | 1.6 | 4.5 | 14.9 | 46 | 31 | 60 | 37 | 11 |
Infliximab | ||||||||||
3 mg/8 weeks + MTX13 | 86 | RCT | 1.8 | 2.8 | 8.4 | NA | NA | 50 | 27 | 8 |
3 mg/8 weeks (with dose increases)+ MTX14,15 | 51 | Observational | 1.5 | 4.0 | 14.1 | 57 | 24 | 41 | 37 | 6 |